Overview
Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Currently, no treatments are available to correct the genetic causes of homocystinuria. However, in order to normalize homocysteine levels, patients can be treated with vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and specific diets. Betaine reduces plasma homocysteine levels in patients with homocystinuria. Although it is present in many food products, the levels found there are insufficient to treat this condition. The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria, and the EMA has approved the use of Amversio (betaine anhydrous, oral powder).
Background
Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Currently, no treatments are available to correct the genetic causes of homocystinuria. However, in order to normalize homocysteine levels, patients can be treated with vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and specific diets. Betaine reduces plasma homocysteine levels in patients with homocystinuria. Although it is present in many food products, the levels found there are insufficient to treat this condition. The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria, and the EMA has approved the use of Amversio (betaine anhydrous, oral powder).
Indication
Betaine is indicated for the treatment of homocystinuria in pediatric and adult patients to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl).
Associated Conditions
- Homocystinuria
- Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
- Homocystinuria due to MTHFR deficiency
- Homocystinuria due to cobalamin cofactor metabolism (cbl) defect
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/03/13 | Phase 2 | Recruiting | |||
2022/04/22 | Phase 3 | Completed | |||
2015/03/31 | Phase 2 | Completed | |||
2014/04/24 | Phase 1 | Completed | |||
2013/09/25 | Phase 2 | Completed | |||
2013/04/24 | Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | ||
2012/12/17 | Phase 4 | Completed | |||
2009/04/16 | Early Phase 1 | Terminated | |||
2008/01/07 | Phase 2 | Completed | |||
2006/07/06 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Rare Disease Therapeutics, Inc. | 66621-4000 | ORAL | 6 g in 1 1 | 10/10/2010 | |
Jaymac Pharma | 64661-650 | ORAL | 500 ug in 1 1 | 6/9/2019 | |
OAKRUM PHARMA, LLC | 72647-900 | ORAL | 1 g in 1 g | 11/10/2022 | |
Recordati Rare Diseases | 52276-400 | ORAL | 1 g in 1 g | 1/11/2023 | |
Orphan Europe SARL | 52276-401 | ORAL | 1 g in 1 g | 3/5/2018 | |
Lukare Medical, LLC | 55792-002 | ORAL | 1 g in 1 g | 5/1/2020 | |
Eton Pharmaceuticals, Inc. | 71863-115 | ORAL | 1 g in 1 g | 12/18/2023 | |
Cosette Pharmaceuticals, Inc. | 0713-0352 | ORAL | 1 g in 1 g | 11/4/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
Authorised | 5/5/2022 | ||
Authorised | 5/5/2022 | ||
Authorised | 5/5/2022 | ||
Authorised | 5/5/2022 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
Orthoplex Hydrozyme | 19983 | Medicine | A | 10/3/1991 | |
NATURE'S WEALTH SUPER FAT BURNERS tablet | 46341 | Medicine | A | 8/23/1993 | |
Compound Capsules | 283037 | Australia Natural Foods And Beverages Pty Ltd | Medicine | A | 11/29/2016 |
CYSTADANE betaine 1g/g oral powder bottle | 57379 | Medicine | A | 9/30/1996 | |
EAGLE TRESOS-B tablet - film coated bottle | 15457 | Medicine | A | 9/27/1991 | |
EAGLE DIGESTAID tablet film-coated bottle | 15464 | Medicine | A | 9/27/1991 |